Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 11/20 | 0.76 |
| ▸ | RARG | P13631 | 11/20 | 0.76 |
| ▸ | RARA | P10276 | 10/20 | 0.76 |
| ▸ | RXRA | P19793 | 8/20 | 0.59 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.59 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.59 |
| ▸ | HNF4A | P41235 | 2/20 | 0.56 |
| ▸ | RXRB | P28702 | 5/20 | 0.51 |
| ▸ | RXRG | P48443 | 3/20 | 0.51 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9133279 | 0.98 | RARB (0.74) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL10563217 | 0.91 | RARB (0.70) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL5712103 | 0.91 | RARB (0.80) | RARBRARGRARARXRACYP26A1 | |
| Terephthalic Acid SCHEMBL27345449 | 0.88 | RARB (0.66) | RARBRARGRARARXRACYP26A1 | |
| Terephthalic Acid SCHEMBL27259372 | 0.88 | RARB (0.66) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL2240683 | 0.88 | RARB (0.64) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL3346290 | 0.88 | RARB (0.64) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL9133271 | 0.86 | RARB (0.60) | RARBRARGRARARXRACYP26A1 | |
| Terephthalic Acid SCHEMBL27346776 | 0.86 | RARB (0.67) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL8703530 | 0.86 | CYP26A1 (0.64) | RARBRARGRARARXRACYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| WO-1996024344-A1 | USE OF RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a) | WARNER-LAMBERT COMPANY (US) | 1996-08-15 | — | — | WO | disclosed |
| US-5489611-A | ADMINISTERING A RETINOID COMPOUND | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| US-5428052-A | Classifiable as retinoids; skin disorders, corneopathy | CENTRE INTERNATIONALE DE RECHERCHES DERMATOLOGIQUES (C.I.R.D.) (FR) | 1995-06-27 | — | — | US | disclosed |
| US-5288744-A | Tetramethyltetrahydronaphthyl benzothiazole for treating skin disorders | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (C.I.R.D.) (FR) | 1994-02-22 | — | — | US | disclosed |
| US-5260295-A | Retinoic acid derivatives, cosmetics, skin disorders | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (C.I.R.D.) (FR) | 1993-11-09 | — | — | US | disclosed |
| US-5059621-A | Treatment of dermatologic ailments linked to keratinization disorder | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (C.I.R.D.) (FR) | 1991-10-22 | — | — | US | disclosed |
| EP-0435681-A1 | Chroman esters of phenols and benzoic acids having retinoid-like activity | ALLERGAN, INC. (US) | 1991-07-03 | — | — | EP | disclosed |
| US-5006550-A | Skin disorder, arthritis, wound healing agents, dry eye syndrome | ALLERGAN, INC. (US) | 1991-04-09 | — | — | US | disclosed |
| US-4920140-A | Skin disorders | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) | 1990-04-24 | — | — | US | disclosed |
| US-4740519-A | Benzo (b) thiophene carboxylate derivatives and pharmaceutical compositions | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) | 1988-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | RARB 899/4885RARG 556/4885RARA 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.